Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 9 clinical trials at NIH that match your search criteria

Cancer by PI: Wilson, Wyndham H. M.D., Ph.D.

Trial and Protocol Number AIDS Related Cancers	Principal Investigator	Referral Contact
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas NCI-01-C-0030	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov

Trial and Protocol Number Leukemia (Adult)	Principal Investigator	Referral Contact
Treatment of Chronic Lymphocytic Leukemia: DNA Microarray Gene Expression Analysis NCI-97-C-0178	Wyndham H. Wilson 301-435-2415	Therese White 301-402-5886 whiteth@mail.nih.gov

Trial and Protocol Number Lymphoma	Principal Investigator	Referral Contact
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas NCI-04-C-0173	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov

Trial and Protocol Number Lymphoma (Adult)	Principal Investigator	Referral Contact
A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCI-07-C-0006	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas NCI-05-C-0252	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics NCI-05-C-0170	Wyndham H. Wilson 301-435-2415	Therese White 301-402-5886 whiteth@mail.nih.gov
Pilot Trial of Alemtuzumab and Dose-Adjusted EPOCH in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas NCI-03-C-0304	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin’s Lymphoma NCI-93-C-0133 (Multi-center study)	Wyndham H. Wilson 301-435-2415	Therese White 301-402-5886 whiteth@mail.nih.gov

Trial and Protocol Number Lymphomatoid Granulomatosis	Principal Investigator	Referral Contact
Treatment and Natural History Study of Lymphomatoid Granulomatosis NCI-94-C-0074	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov

If there are no studies listed for your specific disease type, please search under:

Solid Tumor (advanced malignancy)